- Plasma fractionation involves the separation of plasma into its component proteins, which are then used to treat a variety of conditions such as immune deficiencies, bleeding disorders, and pulmonary diseases
- The growth of this market is primarily driven by the increasing prevalence of rare and chronic diseases, rising demand for immunoglobulins and albumin, and advancements in fractionation technologies
- North America is expected to dominate the plasma fractionations market with a market share of 54.1%, due by a well-established plasma collection infrastructure, high healthcare spending, and robust demand for immunoglobulins and albumin
- Asia-Pacific is expected to be the fastest growing region in the Plasma Fractionation market with a market share of 22.5%, during the forecast period due to increasing healthcare investments, rising awareness of plasma-derived therapies, and growing patient populations with chronic and rare diseases
- Immunoglobulins segment is expected to dominate the market with a market share of 63.7% due to its widespread use in treating primary and secondary immunodeficiency disorders, autoimmune diseases, and neurological conditions
